Status
Conditions
About
The overall survival (OS)of Chronic myeloid leukemia (CML) has been significantly improved since the advent of Tyrosine kinase inhibitors (TKIs) .Nevertheless, there still exists a amount of patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib, nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib,and it aslo has better security when compared to other TKIs(Imatinib, dasatinib, nilotinib).It will be a better chioce for CML patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
There are currently no registered sites for this trial.
Central trial contact
Na Xu, doctor
Start date
Dec 09, 2020 • 4 years ago
End date
Jan 01, 2024 • 1 year ago
Today
Jan 21, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal